Systemic and lung inflammation in 2 phenotypes of chronic obstructive pulmonary disease;Inflamación pulmonar y sistémica en 2 fenotipos de EPOC

Archivos de Bronconeumologia

Volumn 42, Issue 7, 2006, Pages 332-337

  Izquierdo, José Luis ^a   Almonacid, Carlos ^a   Parra, Trinidad ^a   Pérez, Jaime ^a  

^a HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

Author keywords

COPD; Inflammation; Oxidative stress; Phenotype

Indexed keywords

8 ISOPROSTANE; CARBON MONOXIDE; INTERLEUKIN 8; LEUKOTRIENE B4;

ADULT; AGED; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; EMPHYSEMA; HUMAN; INFLAMMATION; LUNG DIFFUSION CAPACITY; LUNG VOLUME; MALE; PHENOTYPE; PNEUMONIA; SMOKING; SYSTEMIC DISEASE;

EID: 33747066140     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13090583     Document Type: Article

References (26)

1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-46.
2. Kim WD, Eidelman D, Izquierdo JL, et al. Centrilobular and panlobular emphysema in smokers. Two distinct morphological and functional entities. Am Rev Respir Dis. 1991;144:1385-90.
3. Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med. 2001;163:1256-76.
4. Cotes JE, Dabbs JM, Elwood PC, et al. Iron-deficiency anaemia: its effect on transfer factor for the lung (diffusing capacity) and ventilation and cardiac frequency during submaximal exercise. Clin Sci. 1972;42:325-35.
5. Engelen MP, Deutz NE, Mostert R, et al. Response of whole-body protein and urea turnover to exercise differs between patients with chronic obstructive pulmonary disease with and without emphysema. Am J Clin Nutr. 2003;77:868-74.
6. Engelen MP, Schools AM, Lamers RJ, et al. Different patterns of chronic tissue wasting among patients with chronic obstructive pulmonary disease. Clin Nutr. 1999;18:275-80.
7. Agusti AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:347-60.
8. Dekhuijzen PN, Aben KK, Dekker I, et al. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;154:813-6.
9. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med. 1999;160:893-8.
10. Montuschi P, Kharitonov SA, Ciabattoni G, et al. Exhaled leukotrienes and prostaglandins in COPD. Thorax. 2003;58:585-8.
11. 4 levels in patients with obstructive pulmonary disease. Chest. 1991;99:289-91.
12. Yamamoto C, Yoneda T, Yoshikawa M, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest. 1997;112:505-10.
13. Montuschi P, Collins JV, Ciabattoni G, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med. 2000;162:1175-7.
14. Montuschi P, Kharitonov SA, Ciabattoni G, et al. Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003;58:585-8.
15. Saetta M, Kim WD, Izquierdo JL, et al. Extent of centrilobular and panacinar emphysema in smokers' lungs: pathological and mechanical implications. Eur Respir J. 1994;7:664-71.
16. Kharitonov SA, Barnes P. Exhaled markers of pulmonary disease. Am J Crit Care Med. 2001;163:1693-722.
17. Izquierdo Alonso JL, Sánchez Hernández I, Fernádez Francés J, et al. Utility of transfer factor to detect different bronchodilator responses in patients with chronic obstructive pulmonary disease. Respiration. 1998;65:282-8.
18. Weir DC, Gove IR, Robertson AS, et al. response to corticosteroids in chronic airflow obstruction: Relationship to emphysema and airways collapse. Eur Respir J. 1991;4:1185-90.
19. Eliasson O, Degraff AC. The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Am Rev Respir Dis. 1985;132:858-64.
20. Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, et al. C-reactive protein in patients with COPD, control smokers, and non-smokers. Thorax. 2006;61:23-8.
21. Montuschi P. Exhaled breath condensate analysis in patients with COPD. Clin Chim Acta. 2005;356:22-34.
22. McLean A, Warren PM, Gillooly M, McNee W, Lamb D. Microscopic and macroscopic measurements of emphysema: relation to carbon monoxide gas transfer. Thorax. 1992;47:144-9.
23. Izquierdo Alonso JL, Juretschke Moragues MA, Ramos Martos A, et al. Utility of complete dead space washout by real time gas analysis in the measurement of transfer factor in patients with chronic airflow limitation. Respiration. 1996;63:339-45.
24. Van Hoydonck PGA, Wuyts WA, Vanaudenaerde BM, et al. Quantitative analysis of 8-isoprostane and hydrogen peroxide in exhaled breath condensate. Eur Respir J. 2004;23;189-92.
25. Hyde RW. I don't know what you guys are measuring but you sue are measuring it. Am J Respir Crit Care Med. 2002;165:561-4.
26. Horvath I, Hunt J, Barnes PJ. On behalf of the ATS/ERS Task Force on Exhaled Breath. ATS/ERS TASK FORCE. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J. 2005;26:523-48.